Respuestas que has esperado por décadas
Por favor escoja la pregunta para ser dirigido a la respuesta
Hay evidencia científica que señala el inicio inmediato como óptimo y que aplaca los síntomas comunes, de manera que el proceso evoluciona sin dolor, sin inflamación, sin infección y que deja señas casi imperceptibles.
El paso I actúa en profundidad y el Paso II es más de acción superficial y de protección. Las capas de producto no se mezclan y actúan independientemente. El paso 2 puede fungir como apósito en aquellos casos que la herida no esté sujeta a trauma.
NO, es tanto para menores, pero sobre todo para mayores. Es el único sistema que mantiene las heridas, incluso crónicas, libres de infección sin usar antibióticos.
Video que ilustra "Cómo se Usa" disponible en la página abajo a la derecha.
Durante 2 décadas que los productos iniciaron a ser usados en humanos, no se ha descrito algún efecto secundario de importancia.
En caso de no encontrar nuestros productos en su farmacia favorita
comuníquese con nosotros al 2241 4706 o al WhatsApp 8855 1008 para
coordinar la entrega. No se conforme con un producto de inferior calidad.
El desarrollo comercial de este avance científico, no está basado sobre la visita al profesional para luego esperar que recomiende un producto, por la sencilla razón de su enorme costo fuera del alcance de los recursos que BioAcyl Corp ha podido reunir, allende del enorme costo del desarrollo que dio a la luz la familia de productos que ofrece.
En su defecto BioAcyl Corp se ha valido de medios digitales y redes sociales para divulgar los conceptos que respaldan la eficacia de los productos.
De manera que, es muy probable que quien busque respaldo con un profesional, este va a desaconsejar su uso sin llevar a cabo una búsqueda en línea o los repositorios que están disponibles para el público y profesionales, los cuales justifican ampliamente el uso por eficacia y seguridad.
Pero el seguimiento virtual que BioAcyl ofrece, hace desvanecer esta negativa en cortísimo tiempo y quien busque en línea o en nuestros repositorios PLUSALUS, el presente y el DOI: The Goldilocks Zone of Healing An unexploited resource for advanced healing, encontrará respuestas concretas. En conclusión, la evidencia demuestra lo contrario a un desaconsejo y quien acate el mismo, perderá avances aplicados muy valiosos. Ver Superioridad de Cubrisoft sobre lo establecido
Bioactil Gel. Es un producto de nueva generación para el manejo de las
lesiones músculoesqueléticas comunes y complicadas, de eficacia sin precedentes. Es de libre venta, no contiene ingredientes controlados, tóxicos, ni posee efectos secundarios. Pueden tenerlo tanto los minisúper y los supermercados importantes, como las farmacias. Su precio es accesible para todos, hecho que finalmente abre el derecho a tener un producto de calidad superior que funciona maravillosamente bien. Quien compra un Bioactil, apoya a que todos puedan disfrutar del beneficio. Esperamos muy cordialmente que nos apoyes.
https://ecom1.bioacyl.com/ocart/index.php?route=common/home
WHO/Sarah Pabst
At the Malbrán Institute in Buenos Aires, Argentina, scientists study bacteria samples from across Latin America to track and control the emergence of antimicrobial resistance (AMR).
© Credits
21 November 2023
Antimicrobials – including antibiotics, antivirals, antifungals, and antiparasitics – are medicines used to prevent and treat infectious diseases in humans, animals and plants.
Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi and parasites no longer respond to antimicrobial medicines. As a result of drug resistance, antibiotics and other antimicrobial medicines become ineffective and infections become difficult or impossible to treat, increasing the risk of disease spread, severe illness, disability and death.
AMR is a natural process that happens over time through genetic changes in pathogens. Its emergence and spread is accelerated by human activity, mainly the misuse and overuse of antimicrobials to treat, prevent or control infections in humans, animals and plants.
Antimicrobial medicines are the cornerstone of modern medicine. The emergence and spread of drug-resistant pathogens threatens our ability to treat common infections and to perform life-saving procedures including cancer chemotherapy and caesarean section, hip replacements, organ transplantation and other surgeries.
In addition, drug-resistant infections impact the health of animals and plants, reduce productivity in farms, and threaten food security.
AMR has significant costs for both health systems and national economies overall. For example, it creates need for more expensive and intensive care, affects productivity of patients or their caregivers through prolonged hospital stays, and harms agricultural productivity.
AMR is a problem for all countries at all income levels. Its spread does not recognize country borders. Contributing factors include lack of access to clean water, sanitation and hygiene (WASH) for both humans and animals; poor infection and disease prevention and control in homes, healthcare facilities and farms; poor access to quality and affordable vaccines, diagnostics and medicines; lack of awareness and knowledge; and lack of enforcement of relevant legislation. People living in low-resource settings and vulnerable populations are especially impacted by both the drivers and consequences of AMR.
The global rise in antibiotic resistance poses a significant threat, diminishing the efficacy of common antibiotics against widespread bacterial infections. The 2022 Global Antimicrobial Resistance and Use Surveillance System (GLASS) report highlights alarming resistance rates among prevalent bacterial pathogens. Median reported rates in 76 countries of 42% for third-generation cephalosporin-resistant E. coli and 35% for methicillin-resistant Staphylococcus aureus are a major concern. For urinary tract infections caused by E. coli, 1 in 5 cases exhibited reduced susceptibility to standard antibiotics like ampicillin, co-trimoxazole, and fluoroquinolones in 2020. This is making it harder to effectively treat common infections.
Klebsiella pneumoniae, a common intestinal bacterium, also showed elevated resistance levels against critical antibiotics. Increased levels of resistance potentially lead to heightened utilization of last-resort drugs like carbapenems, for which resistance is in turn being observed across multiple regions. As the effectiveness of these last-resort drugs is compromised, the risks increase of infections that cannot be treated. Projections by the Organization for Economic Cooperation and Development (OECD) indicate an anticipated twofold surge in resistance to last-resort antibiotics by 2035, compared to 2005 levels, underscoring the urgent need for robust antimicrobial stewardship practices and enhanced surveillance coverage worldwide.
As drug-resistant fungal infections increase, WHO is monitoring their magnitude and public health impact. Fungal infections can be difficult to treat, including due to drug-drug interactions for patients with other infections (e.g. HIV). The emergence and spread of multi-drug resistant Candida auris, an invasive fungal infection, is of particular concern. Development of WHO’s Fungal Priority Pathogens List (see below) included a comprehensive review of fungal infections and drug-resistant fungi globally.
HIV drug resistance (HIVDR) is caused by changes in the HIV genome that affect the ability of antiretroviral (ARV) drugs to block the replication of the virus. HIVDR can either be transmitted at the time of infection or acquired because of inadequate adherence to treatment or drug-drug interactions. HIVDR can lead to increased HIV infections and HIV-associated morbidity and mortality. WHO recommends that countries routinely implement HIVDR surveys to inform the selection of optimal ARV drug regimens for HIV prevention and treatment.
Tuberculosis (TB) is a major contributor to antimicrobial resistance. Multidrug-resistant tuberculosis (MDR-TB) is a form of TB caused by bacteria that do not respond to isoniazid and rifampicin, the two most effective first-line TB drugs. MDR-TB is treatable and curable by using second-line drugs, but these medicines are expensive and toxic, and in some cases more extensive drug resistance can develop. TB caused by bacteria that do not respond to the most effective second-line TB drugs can leave patients with very limited treatment options. MDR-TB is therefore a public health crisis and threat to health security. Only about 2 in 5 people with drug resistant TB accessed treatment in 2022.
The emergence of drug-resistant parasites is a major threat to malaria control. Artemisinin-based combination therapies (ACTs) are the recommended first-line treatment for uncomplicated Plasmodium falciparum malaria and are used by most malaria endemic countries. Emergence of partial resistance to artemisinin and/or partner drugs in ACTs makes selecting the right treatment more challenging and requires close monitoring. In the Greater Mekong Subregion, partial resistance to artemisinin or a partner drug has been confirmed in several countries since 2001. In the WHO Eastern Mediterranean Region, resistance to a partner drug, sulfadoxine-pyrimethamine, led in some countries to treatment failure requiring a change to another ACT. In Africa, mutations linked to artemisinin partial resistance have been observed in several countries. ACTs that have been tested remain efficacious, but further spread of resistance could be a major public health challenge and improved surveillance is vital.
The emergence of drug resistance against medicines for neglected tropical diseases (NTDs) is a significant threat to programmes to control, eliminate and eradicate NTDs, which especially affect vulnerable and marginalized populations. Resistance has been reported in leprosy medicines (dapsone, rifampicine and clofazimine) in several countries, in several anti-helminthics (while resistance has so far only been observed in use in animals, which is a serious concern for the veterinary sector, some of these medicines are also used in humans), in medicines used to treat human African trypanosomiasis (melarsoprol) and leishmaniasis (pentavalent antimonials, miltefosine), and others. It is important to monitor resistance and drug efficacy, put in place strategies to delay or curb resistance, and strengthen the pipeline of second-line medicines for NTDs. For example, WHO provides guidance for surveillance of resistance for the global leprosy elimination programme, and support to control distribution and monitor the standardized use, safety and efficacy of medicines, including donated medicines, in NTD programmes.
AMR is a complex problem that requires both sector-specific actions in the human health, food production, animal and environmental sectors, and a coordinated approach across these sectors. One Health refers to an integrated, unifying approach that aims to achieve optimal and sustainable health outcomes for people, animals and ecosystems. It recognizes that the health of humans, domestic and wild animals, plants and the wider environment are closely linked and inter-dependent. The One Health approach to preventing and controlling AMR brings together stakeholders from relevant sectors to communicate and work together in the design, implementation and monitoring of programmes, policies, legislation and research to mitigate AMR and attain better health and economic outcomes.
To address AMR globally, countries adopted the Global Action Plan (GAP) on AMR during the 2015 World Health Assembly and committed to the development and implementation of multisectoral national action plans with a One Health approach to tackle AMR. The GAP was subsequently endorsed by the Governing Bodies of the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (WOAH, formerly known as OIE) and the United Nations Environment Program.
To coordinate the One Health global response to AMR, WHO works closely with the Food and Agriculture Organization of the United Nations (FAO), the UN Environment Programme (UNEP) and the World Organisation for Animal Health (WOAH). The 4 organizations (FAO, UNEP, WHO and WOAH) are known as the Quadripartite. A quadripartite joint secretariat is hosted by WHO to drive multi-stakeholder engagement in AMR. This has supported establishment of the Global Leaders Group on AMR, which began its work in November 2020, and the Multi-Stakeholder Partnership Platform, which was launched in November 2022, and several technical working groups.
In March 2022, United Nations General Assembly resolution A/RES/76/257 established a second High-level Meeting on AMR to be held in 2024, in collaboration with the Quadripartite Organizations and with the support of the Global Leaders Group. In October 2023, The President of the General Assembly appointed the Permanent Representatives of Barbados and Malta to co-facilitate the high-level meeting. The high-level meeting is an important opportunity for countries to make ambitious commitments and agree targets, and the Quadripartite Joint Secretariat is working closely with the co-facilitators and Global Leaders Group to ensure optimal participation and inputs from the human, animal, agri-food and the environment sectors.
In addition, three Global High-level Ministerial Conferences on AMR, in the Netherlands in 2014 and 2019, and in Oman in 2022, led to the Global Action Plan, the AMR Multi-Partner Trust Fund, and groundbreaking multisectoral AMR targets. A fourth high-level ministerial conference will be hosted by the Kingdom of Saudi Arabia in 2024.
World AMR Awareness Week (WAAW) is a global campaign to raise awareness, understanding and best practices with the public, One Health stakeholders, and other policymakers. One of WHO’s official health campaigns since 2015, WAAW is celebrated from 18 to 24 November every year.
As of November 2023, 178 countries had developed AMR national action plans aligned with the GAP. To ensure sustained progress, countries need to establish a functioning multisectoral AMR governance mechanism, prioritize activities, develop a costed operational plan, mobilize resources (both domestic and external), and effectively implement their plan. Monitoring mechanisms are needed to track progress, identify challenges and report periodically. To globally track the progress in AMR national action plan implementation, countries have committed to completing the multisectoral annual Tracking AMR Country Self-Assessment Survey (TrACSS) that was launched in 2016 with results published at https://www.amrcountryprogress.org/.
To address AMR in a programmatic manner that puts people, their needs and equitable access to health services at the centre of the AMR response in the community, in primary care, secondary and tertiary care, and at national and/or subnational level, WHO has developed the People-centred approach to addressing antimicrobial resistance in human health and WHO core package of interventions to support national action plans. This focuses on preventing infections and ensuring universal access to health services for quality diagnosis and appropriate treatment. As a crucial part of their AMR response, countries can integrate the core package of AMR interventions in national plans and strategies for universal health coverage and health emergency preparedness and response.
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials. The education of the health workforce is of crucial importance, as they form the front line in safeguarding the effectiveness of antimicrobial medicines. WHO guides countries to develop and implement Antimicrobial Stewardship Programmes as one of the most cost-effective interventions to optimize the use of antimicrobial medicines, improve patient outcomes and reduce AMR and health care-associated infections.
To improve access to appropriate treatment and reduce inappropriate use of antibiotics, WHO developed the AWaRe (Access, Watch, Reserve) classification of antibiotics. The WHO AWaRe antibiotic book provides concise, evidence-based guidance on the choice of antibiotic, dose, route of administration, and duration of treatment for more than 30 of the most common clinical infections in children and adults in both primary health care and hospital settings.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels. GLASS progressively incorporates data from surveillance of AMR in humans, surveillance of the use and consumption of antimicrobials, and integrated AMR data in the One Health sectors including the food chain and in the environment.
GLASS provides a standardized approach to the collection, analysis, interpretation and sharing of data by countries, territories and areas. It also monitors the status of existing and new national surveillance systems, with emphasis on representativeness and quality of data collection. Some WHO regions have established surveillance networks that provide technical support to countries and facilitate enrollment into GLASS.
WHO is committed especially to supporting low- and middle-income countries to improve data collection and usage for policymaking, both through GLASS and by supporting nationally representative AMR prevalence surveys.
The clinical pipeline of new antimicrobials is almost dry and there is a pipeline and access crisis for antibiotics. WHO’s latest annual review of the pre-clinical and clinical antibacterial pipelines identified 27 antibiotics in clinical development that address WHO bacterial priority pathogens, of which only 6 were classified as innovative. In addition, a lack of access to quality antimicrobials and shortages of generic off-patent antibiotics affect countries across all levels of income and development.
To guide research and development into new antimicrobials, diagnostics and vaccines, and inform public health action, WHO developed the first WHO bacterial priority pathogens list in 2017 and updated this in 2023 (publication forthcoming), and published the WHO fungal priority pathogen list in 2022.
To help fill the major gaps in R&D for antimicrobials, vaccines and diagnostic tools, WHO works closely with organizations such as the Global Antibiotic Research & Development Partnership (GARDP), the AMR Action Fund, and the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Various governments are also piloting different models to incentivize research and development of newer antimicrobials to ultimately ensure access to treatment.
Greater innovation and investment are also required in epidemiological and operational research. WHO has outlined 40 priority research topics for AMR in human health and, with the Quadripartite organizations, a One Health priority research agenda for AMR.
References
1. Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet; 399(10325): P629-655. DOI: https://doi.org/10.1016/S0140-6736(21)02724-0
2. Drug-Resistant Infections: A Threat to Our Economic future (March 2027) https://www.worldbank.org/en/topic/health/publication/drug-resistant-infections-a-threat-to-our-economic-future
Related
News
WHO reports widespread overuse of antibiotics in patients hospitalized with COVID-19 26 April 2024
WHO launches data visualization dashboard on antimicrobial resistance and use 13 February 2024
Feature stories
Patients’ stories paint a vivid picture of antimicrobial resistance 17 November 2023
Donors making a difference: Climate change and its impact on health 9 November 2022
Infection prevention and control in Germany 18 October 2022
More
Nuevo conocimiento que libera a productos seguros del manejo exclusivo de los profesionales eleva ese conocimiento a nivel público y disponible para que usted también conozca las nuevas y grandes ventajas.
Muchos dirán "demasiado bueno para que sea cierto". Pero la evidencia acumulada ratifica el nivel excepcional de la eficacia de los productos y que son la respuesta a:
¿Por qué no puede ser bueno y por qué no puede ser cierto?
Los nuevos conocimientos aplicados dejan rezagados a los métodos y técnicas del establecimiento y, harto demostrado, que ya no funcionan,
En una caminata. es muy probable sufrir algún tipo de lesión,
Quien ya conoce Bioactil sabe que eso es algo del pasado y que no puede faltar en la caminata. Le deseamos un feliz retorno libre de molestias con Bioactil. Es ideal para el manejo del dolor tópico y lesiones, que supera a los AINES y libre de efectos secundarios, Puede usar Bioactil antes y después de las caminatas o de cualquier actividad fisica.
https://bioacyl.com/index.php/inicio/dolor/el-doble-filo-de-los-aines
Estos productos tienen un reverso positivo de la medalla, Son eficaces sea para lesiones menores banales que para lesiones mayores que ameritan hospitalización. En ambos casos el uso inmediato luego de una lesión es fundamental, debido al hecho que así se capta la respuesta constitutiva celular de la inmunidad innata que induce beneficios sorprendentes no logrados anteriormente. Es una cicatrización sin dolor, sin inflamación, sin infección que si apenas deja marca. Por tanto, de todo punto de vista, los productos pueden ser recomendados a profesionales.
El vehículo cambió de simple gel a polielectrolitos/nano.partículas que modula la entrega, en vez de descarga total y súbita del gel, y acorta el efecto resolutivo a un 50% del tiempo de aplicación, pero prolongando el efecto de cada aplicación singular durante el día. En resumen, se absorbe mejor, es más rápido en aliviar y dura más tiempo el alivio. Se usa menos producto que con gel y rinde más. Ver ilustración
https://bioacyl.com/index.php/inicio/holobionte/la-mejora-de-metodo-de-entrega-necesita-ser-entendida-por-los-usuarios
Narración del desarrollo de
BioAcyl Corp
Con el descubrimiento original de nuestro laboratorio del control de tejido/microambiente, a fínales del siglo XX, nace la posibilidad de desarrollo de toda una familia de productos tópicos y transdérmicos de eficacia excepcional y seguridad máxima. Esto aunado a la entrega en vehículos a base de polilecetrolitos/nano.partículas. ha permitido aprovechar polianiones que al mismo tiempo poseen actividad biológica, en potenciar los alcances de la idea primaria. Al mismo tiempo se introdujo el uso práctico de la utilización de glicanos (glicobiología) que les confiere a los productos visos autacoides. El conjunto permite formular productos de eficacia y seguridad antes no alcanzables.